REG - AstraZeneca PLC - AstraZeneca prices a $3bn bond issue

AstraZenecaAnnouncement

15/08/2018 07:05

RNS Number : 8190X
AstraZeneca PLC
15 August 2018
 


15 August 2018 07:00 BST
 
AstraZeneca prices a $3bn bond issue
 
AstraZeneca PLC announces that, on 14 August 2018, it priced a four tranche global bond offering totalling $3bn. The offering is expected to close on 17 August 2018, subject to customary closing conditions. AstraZeneca expects to use the net proceeds of the issue for general corporate purposes, which may include the refinancing of existing indebtedness. The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of the following four tranches:
 
·     $0.85bn of fixed rate notes with a coupon of 3.500%, maturing 17 August 2023;  
·     $0.40bn of floating rate notes with a coupon of 3 month LIBOR plus 0.665%, maturing 17 August 2023;
·     $1.00bn of fixed rate notes with a coupon of 4.000%, maturing 17 January 2029; and
·     $0.75bn of fixed rate notes with a coupon of 4.375%, maturing 17 August 2048.
 
Citigroup, Deutsche Bank Securities, Goldman Sachs & Co. LLC and J.P. Morgan acted as joint book-running managers on the transaction. The notes will be issued under AstraZeneca's effective shelf registration statement on Form F-3, which AstraZeneca filed with the SEC on 22 November 2016. The offering is being made solely by means of the prospectus contained within that shelf registration statement, along with a prospectus supplement forming part of the effective registration statement, which investors should read.
 
A copy of the prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146 or by email at prospectus@citi.com; Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, by telephone at (800) 503-4611, or by email at prospectus.cpdg@db.com; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, by facsimile at (212) 902-9316 or by emailing Prospectus-ny@ny.email.gs.com or J.P. Morgan Securities LLC, 383 Madison Avenue, New York, NY 10179, Attention: Investment Grade Syndicate Desk or by telephone collect at (212) 834-4533. You may also download these documents for free by visiting EDGAR on the SEC website at www.sec.gov.
 
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
 
The bond issuance does not impact the Company's financial guidance for 2018.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 
 
Cautionary Statements Regarding Forward-Looking Statements
This announcement contains certain forward-looking statements with respect to the operations, performance and financial condition of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this announcement and AstraZeneca undertakes no obligation to update these forward-looking statements.
 



Media Relations












Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen


 
 


+44 203 749 5712




Josie Afolabi






+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Henry Wheeler


Oncology


+44 203 749 5797




Mitchell Chan


Oncology; Other


+1 240 477 3771




Christer Gruvris


Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free






+1 866 381 7277

















Adrian Kemp

Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IODUVURRWUAWARR